Anatabine is a small alkaloid found in tobacco and plants in the solanaceae family (such as eggplant and peppers). It possesses antiinflammatory properties via inhibiting a protein known as STAT3, but this may occur at too high of an oral dose to matter with nutritional supplementation.

This page features 20 unique references to scientific papers.

Confused about what actually Works?
MUST GET: Supplement Stack Guides - Saving You Money & Time


Anatabine is an alkaloid similar to Nicotine that is found in the same sources, and is currently being investigated for its antiinflammatory properties. It appears to work via inhibiting the STAT3 protein which then inhibits nF-kB activation (a mechanism of action similar to Boswellia serrata and Feverfew, among other antiinflammatory agents) and preliminary evidence in animals suggests that these benefits may be useful for autoimmune diseases and Alzheimer's disease.

Unfortunately, currently the dosages being used are much higher than the doses currently on the supplement market. While dietary supplements of anatabine tend to be dosed at 1mg per serving, the lowest effective dose in mice was a 2mg/kg injection (0.16mg/kg in humans, or 11mg for a 150lb person) while oral studies have used a dosage that is equivalent to 1-1.6mg/kg in humans (for our 150lb person, this would be a dosage range of 68-110mg). While this is a dosage that is significantly lower than other supplements (which usually have an active dose in the 300-500mg range), it is still much lower than is currently available, and the one human study failed to find any anti-inflammatory effects even at a dose that was 6-12 times higher than the currently sold doses.

Due to the limitations in the market at the moment, anatabine may not be a practical antiinflammatory to use.

Follow this Page for updates

Confused about Supplements?
Get the Stack Guides

Also Known As

Anatabloc (Brand Name)

Animal research on anatabine have used oral intakes of 12.5-20mg/kg in mice for the purpose of reducing autoimmune diseases, which suggests a human preliminary dosage of:

  • 70-110 mg for a 150lb person
  • 90-150 mg for a 200lb person
  • 110-180 mg for a 250lb person

The Human Effect Matrix looks at human studies (excluding animal/petri-dish studies) to tell you what effect Anatabine has in your body, and how strong these effects are.
GradeLevel of Evidence
ARobust research conducted with repeated double blind clinical trials
BMultiple studies where at least two are double-blind and placebo controlled
CSingle double blind study or multiple cohort studies
DUncontrolled or observational studies only
Level of Evidence
Magnitude of Effect Size
Scientific ConsensusComments
CMuscle Damage

The progression of recovery after a novel workout (when measured over three days) was unaffected by 6-12mg anatabine

CPower Output

Strength recovery over the course of three days recovery was not significantly improved by 6-12mg anatabine

CMuscle Soreness

Perceived muscle soreness and pain from a workout was unaffected by anatabine supplementation.

CBlood Pressure

6-12mg anatabine does not appear to significantly influence blood pressure in otherwise healthy persons.

CHeart Rate

There is no significant influence on heart rate seen with 6-12mg anatabine in otherwise healthy persons

Disagree? Join the Anatabine Discussion

Table of Contents:

Edit1. Sources and Structure

1.1. Sources

Anatabine is an alkaloid found in tobacco and the solanaceae family of plants. This alkaloid is structurally similar to Nicotine, and is an analogue of both nornicotine and anabasine (other alkaloids in the same plant family).[1]

It is found in:

  • Tobacco in the range of 927-1390μg/g[2] or on average 554μg per cigarette (range of 130-1120μg; American cigarettes containing 500-550μg)[1]
Anatabine is a tobacco alkaloid similar to nicotine, and is found in the same plants

1.2. Structure and Properties

Anatabine is an alkaloid with structural similarity to Nicotine, and closer structure similarity to anabasine (which is anatabine without the double bond in the right ring pictured below).

Edit2. Neurology

2.1. Cholinergic Neurotransmission

In vitro, anatabine has been noted to have bind to the α3β4 receptor with similar affinity as Nicotine.[3]

May interact with nicotinic cholinergic receptors, although this is not well researched

2.2. Alzheimer's Disease

Anatabine has been found to reduce Aβ production (both Aβ1–40 and Aβ1–42) with an IC50 of around 640µg/mL, and it appeared to mostly inhibit β-cleavage of APP.[4] As this is known to occur with NF-kB inhibition[5][6] anatabine was then tested on the protein and it was found to inhibit NF-kB activation from TNF-α with a similar IC50 value[4] and nicotine was found to be inactive at the same concentrations tested. It has been noted elsewhere that this inhibitory effect on NF-kB is secondary to inhibiting STAT3 phosphorylation at 600-800µg/mL[7] although concnetrations as low as 10µg/mL can inhibit LPS-induced NF-kB activity and 400µg/mL can fully abolish IL-1β secretion induced by LPS.[7]

Nicotine has been found to inhibit Aβ production by regulating BACE-1 transcription in cells that express its receptor (α4β2 nicotinic acetylcholine receptor)[8] and anatabine has also been found to downregulate BACE-1 mRNA, which was credited to NF-kB inhibition (known to regulate BACE-1[9]). Activation of the nicotinic receptors can inhibit NF-kB[10] via STAT3[11] but nicotine seems to require a cholinergic receptor whereas anatabine does not.[4]

When injected into mice at 0.5-2mg/kg, only the higher dose was able to reduce brain and plasma Aβ concentrations to near control levels (in plasma) and by about 25% (brain)[4] and this dose has been noted to exert anti-inflammatory effects by reducing C-reactive protein[4] as well as IL-1β, IL-6, and TNF-α.[7]

Anatabine is a STAT3 inhibitor, which then inhibits NF-kB and exerts an anti-inflammatory effect. This appears to be active following injections of anatabine and may be of therapeutic benefit to Alzheimer's Disease

Edit3. Cardiovascular Health

3.1. Blood Pressure

Anatabine has structural similarity to Nicotine, and since nicotine is able to acutely increase heart rate and blood pressure[12] anatabine has been investigated for its ability to do the same; it has since failed to significantly influence blood pressure or heart rate.[13]

Currently no significant interactions between anatabine and cardiovascular function are known

Edit4. Inflammation and Immunology

4.1. Mechanisms

Incubation of macrophages with 250-350μM was able to inhibit an IFN-γ and LPS induced increases in iNOS and COX-2 mRNA levels, suggesting antiinflammatory effects.[14]

May have general antiinflammatory properties at moderately high concentrations

4.2. Autoimmune Diseases

Despite the large amount of adverse health effects associated with tobacco smoking, both ulcerative colitis[15][16] and autoimmune (Hashimoto's) thyroiditis[17][18] have noted benefits associated with smoking. This is currently thought to be due to the antiinflammatory properties of nicotine via the α7 nicotinic receptor[19] (inhibits STAT3 and then NF-kB), but anatabine is also being tested.

In mice inflicted with experimental autoimmune thyroiditis and concurrently supplemented orally with approximately 12.5mg/kg anatabine, occurrence of thyroiditis and the antibody response were significantly reduced.[14] Autoimmune encephalomyelitis (research model for Multiple sclerosis) also sees clinical benefit in response to 20mg/kg anatabine in mice, although antibodies were not affected in this study.[20]

Appears to be beneficial for rodents with autoimmune diseases in high oral doses

Edit5. Physical Exercise and Skeletal Muscle

5.1. Muscle Soreness and Damage

Supplementation of 6-12mg anatabine (via lozenges that also conferred 834-1668IU vitamin A and 66-132IU Vitamin D) for ten days prior to physical exercise testing in otherwise healthy young men failed to outperform placebo (which contained the vitamins) in reducing muscle soreness or power output when measured over the next three days.[13]

The lone study in humans assessing the antiinflammatory properties of anatabine failed to find any significant influence of supplementation


  1. Wu W, Ashley DL, Watson CH. Determination of nicotine and other minor alkaloids in international cigarettes by solid-phase microextraction and gas chromatography/mass spectrometry. Anal Chem. (2002)
  2. Lisko JG, et al. Application of GC-MS/MS for the analysis of tobacco alkaloids in cigarette filler and various tobacco species. Anal Chem. (2013)
  3. Screening of Tobacco Smoke Condensate for Nicotinic Acetylcholine Receptor Ligands using Cellular Membrane Affinity Chromatography Columns and Missing Peak Chromatography
  4. Paris D, et al. Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. Eur J Pharmacol. (2011)
  5. Paris D, et al. Inhibition of Abeta production by NF-kappaB inhibitors. Neurosci Lett. (2007)
  6. Paris D, et al. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J Neuroinflammation. (2010)
  7. Paris D, et al. Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation. Eur J Pharmacol. (2013)
  8. Nicotine decreases beta-amyloid through regulating BACE1 transcription in SH-EP1-α4β2 nAChR-APP695 cells
  9. Buggia-Prevot V, et al. NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42. J Biol Chem. (2008)
  10. Yoshikawa H, et al. Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol. (2006)
  11. Peña G, et al. Unphosphorylated STAT3 modulates alpha 7 nicotinic receptor signaling and cytokine production in sepsis. Eur J Immunol. (2010)
  12. Haass M, Kübler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther. (1997)
  13. Jenkins ND, et al. The effects of anatabine on non-invasive indicators of muscle damage: a randomized, double-blind, placebo-controlled, crossover study. J Int Soc Sports Nutr. (2013)
  14. Caturegli P, et al. Anatabine ameliorates experimental autoimmune thyroiditis. Endocrinology. (2012)
  15. Boyko EJ, et al. Effects of cigarette smoking on the clinical course of ulcerative colitis. Scand J Gastroenterol. (1988)
  16. Calabrese E, et al. Low-dose smoking resumption in ex-smokers with refractory ulcerative colitis. J Crohns Colitis. (2012)
  17. Belin RM, et al. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. (2004)
  18. Pedersen IB, et al. Smoking is negatively associated with the presence of thyroglobulin autoantibody and to a lesser degree with thyroid peroxidase autoantibody in serum: a population study. Eur J Endocrinol. (2008)
  19. Bencherif M, et al. Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell Mol Life Sci. (2011)
  20. Paris D, et al. Amelioration of experimental autoimmune encephalomyelitis by anatabine. PLoS One. (2013)

(Common phrases used by users for this page include what is anatabine?, nf kb anatabine, health benefits of anatabine, anatabine nfkb inhibitor, anatabind, Anatabine Studies)

(Users who contributed to this page include )